#ProtectUrLife Amgen Educational Event from Verkehrshaus Lucerne Offers Free Health Examinations to Detect Increased Risk of Cardiovascular Disease or Osteoporosis 2

#ProtectUrLife Amgen Educational Event from Verkehrshaus Lucerne Offers Free Health Examinations to Detect Increased Risk of Cardiovascular Disease or Osteoporosis

11/10/2019 – 09:36

Amgen Switzerland AG

#ProtectUrLife Amgen Educational Event from Verkehrshaus Lucerne Offers Free Health Examinations to Detect Increased Risk of Cardiovascular Disease or Osteoporosis

Red Cross (ots)

The Swiss Amgen will host for the second time on November 16-17, 2019
#ProtectUrLife event by. Those interested can do theirs
Bone health and its cardiovascular risk factors in
Free for Verkehrshaus Lucerne and get it
inform about a healthy lifestyle. There is a possibility of approx.
A free 20 minute risk check is required
Interview with patient organizations and then on
You should consult a doctor. Amgen runs these
Awareness raising campaign in Switzerland with the EU
Organization of patients OsteoSwiss, Rheumaliga Lucerne and
Unterwalden and Swiss Heart Foundation.

European campaign launched by Amgen in 2018
#ProtectUrLife seeks to prevent and dispose of it
To improve cardiovascular disease and osteoporosis – two
Diseases that are often diagnosed and common
also they are not treated appropriately. #ProtectUrLife
The projections provided help reduce individual risk
Heart attack and stroke based on risk factors such as
Cholesterol levels as well as the risk of osteoporosis via a
Risk Assessment (Fracture Risk Assessment Tool FOX® (1), www.SVGO.ch)
determine. Again in 2019 by EIT Health
The co-financing initiative takes place in 5 European locations.

«After the successful launch of #ProtectUrLife in Zurich
Last year we were pleased to announce this year with Osteoswiss
Rheumaliga Lucerne and Unterwalden and the Swiss
The Heart Foundation is working together on this great initiative at
this year in Lucerne, "says Henrik Asmussen,
Managing Director of Amgen in Switzerland. «The program should be finished
Educate people about the risks and help the public in prevention
Take measures that contribute to the deepening of life
Events like heart attack, stroke and bone fracture too
prevent. "

Another goal of #ProtectUrLife is to bring together different actors
Health care and health policy to achieve this
Awareness of detecting and preventing these diseases
increase sustainably. Musculoskeletal and cardiovascular
(HKL) diseases account for 30% of the total cost in Switzerland
Health system responsible (2)

Osteoporosis and its consequences cost our health care every year
about CHF 2 billion, caused by hospital days, surgeries,
Rehabilitation and real estate (3). There is a lack of broader education,
systematic review, risk-based reimbursement
Bone densitometry and effective treatment pathways in
Secondary prevention, ie if it already has to do with osteoporosis
There was a break. How to manage osteoporosis in a hospital?
Switzerland can improve sustainably, so talk a week ago
#ProtectUrLife (November 9, 2019 at 2:30 pm) during the fair
"Zukunft Alter" (Lucerne Fair) Ruth Humbel, Vice President
National Council Health Commission, Dr. Sigrid Jehle-Kunz,
Head of the Osteoporosis Center Anna, Lucerne and one affected
Osteoporosis patient moderated by Emil Mahnig, President
patient organization OsteoSwiss.

About osteoporosis

In Switzerland, 400,000 people (4) have osteoporosis.
Every other woman and every fifth man over the age of 50 suffers from one
Fracture associated with osteoporosis. (5), (6) For these patients doubled
the likelihood of another fracture in the future
suffering, (7)

Still, according to a recent study in Switzerland
Only every third woman has been treated with an increased risk of fracture. in
this is what most untreated women at risk of fracture do
The absence of a recorded diagnosis of osteoporosis that
The main obstacle to therapy. (8)

"Osteoporosis is a chronic disease and is also called
is called "silent bone loss," since the disease long no
Symptoms are usually only in the advanced phase
it is diagnosed. There is an increased risk of breakage in falls,
which often leads to a loss of independence and long term
cause of disability. Those interested can participate in the #ProtectUrLife event
and Lucerne to determine the risk of rupture and find out if
further clarifications are needed and which are conservative or
Medicinal measures against the development of osteoporosis
or existing osteoporosis is possible. "
Sigrid Jehle-Kunz, Head of the Osteoporosis Center Anna, Lucerne.

«ProtectUrLife offers a great opportunity to get important information about
to experience his bone health. Who knows more about his skeleton
and can be counseled, can prevent in daily life on time or
be treated with custom therapies that cause a lot of suffering
it can prevent osteoporotic fractures and
Spinal fractures go hand in hand, ”adds Emil Mahnig, president
OsteoSwiss, added.

The World Health Organization has osteoporosis for public health
Explained crisis. (9) International osteoporosis based in Nyon
The Foundation (IOF) is calling on governments around the world to prevent osteoporosis
Give priority to healthcare (10).

About cardiovascular disease

Cardiovascular disease accounts for 32% of Swiss patients
the most common cause of death (11) and with 21,000 hospitalizations
the third most common cause of hospitalization (12) in adulthood.
Myocardial infarction occurs 15,000 times (13), ischemic
Strokes 13,000 times (14). After the onset of acute
Coronary syndrome (ACS, myocardial infarction or unstable angina)
the risk of cardiovascular mortality has been around for five years
20%, (15)

Similar to osteoporosis in Switzerland
cardiovascular disease significant differences in treatment: this
although the main risk factors are –
Hyperlipidemia, smoking, high blood pressure, diabetes, obesity,
Psychosocial factors, diet and lack of exercise – long ago
(16) Sustainable reduction
LDL cholesterol levels have significant cardiovascular
Risk reduction included. This is how it lowers LDL cholesterol
by 1 mmol / L for 5 years until reduction of the cardiovascular system
21% risk (17), (18). However, the recommended goal (19) of
1.4 mmol / l only in every tenth patient (10.7%) after acute illness
Coronary syndrome reaches (20) though LDL cholesterol
proven to be the most important risk factor
Cardiovascular disease (21) is. Overall, the share of
Individuals with elevated LDL cholesterol from 2002 to 2012
increased from 7% to 11%. (22)

In 2011, the cost of treatment was more cardiovascular
Diseases with CHF 10.1 billion accounted for approximately 16% of the total
Medical expenses in Switzerland. (23) About the same
the same amounts of indirect medical expenses
(Loss of productivity) (24): This is how the assessment of the data showed
for Switzerland that patients in the first year after acute
Coronary syndrome (ACS) misses an average of 75 working days and
four more days due to reduced efficiency at
He lost his job. Generally, an indirect amount
The cost of these lost productivity averages CHF 43,206
per patient, at a direct cost of 26 & # 39; 563 CHF
A total cost of CHF 69 & # 39; per heart attack. (25) The
Incidentally, the cost share for medicines here is CHF 0.8 billion
quite low. (26)

About #ProtectUrLife

The #ProtectUrLife campaign aims to promote bone and heart health
improve. This is two days
Enlightenment event for young and old people about osteoporosis
and cardiovascular disease with numerous free
Offered like Risk Checking, sharing information throughout
Events, education and knowledge transfer. Initiative
#ProtectUrLife is also intended to help cities and policy makers
enable the situation to develop sustainable health systems that
to benefit their residents.

The 2018 European campaign launched by Amgen u
Collaboration with EIT Health, Technical University
Munich, University of Barcelona and BePatient
with the support of the International Osteoporosis Foundation (IOF).
During last year's events in five European
About 250 people over 50 are screened in the capitals.
Results of cardiovascular and bone examination
2018 showed that over a 10 year period, 10% of that
Participants very high or high risk for lethal
Heart disease, 74% have a medium risk of death
Heart disease and over 22% is at high risk for one
have a greater osteoporotic bone fracture. This year
The campaign was or will be in five major European cities
continued: Paris, 31 August – 1 September, Munich and Malaga,
Nov. 15-16, Lucerne, Nov. 16-17, and Rimini, Nov. 22.
through November 24th. For more information on the campaign, visit
www.protecturlife.eu and follow us
www.twitter.com/protecturlife and www.facebook.com/ProtectUrLife19/.

About Amgen

Amgen is independent of world leaders
A biotechnology company with almost 20,000 employees
has represented nearly 100 countries worldwide for over 35 years. IN
We work in Switzerland at our location in Rotkreuz with about 320
Employees help patients on a daily basis. Use worldwide
Every year, millions of patients are severe or rare
Diseases of our therapies. Our medicines are used in medicines
Nephrology, cardiology, hematology, oncology, bone health
and is used in various inflammatory diseases. following
Original preparations also include biosimilars in our portfolio. me
have a diverse pipeline.

About OsteoSwiss

OsteoSwiss was founded in 1996 under the name donna mobile
established and since then sees himself as an independent patient and
A non-profit organization, helping people help themselves downtown
stands. Changing the name of OsteoSwiss became a fact
Keep in mind that osteoporosis affects both women and men
worries. OsteoSwiss has been in the public eye all these years
– but also in professional circles – as serious, competent
An organization that makes an important contribution
Bone health and osteoporosis education. The club continues
from its inception, to prevention in Switzerland,
The diagnosis and treatment of osteoporosis are also taken into account
be available in a timely manner to anyone affected and at risk
could be. The ultimate goal is to promote bone awareness
and maintain or improve the quality of life of the diseased

About Luzen and Unterwald

People suffering from rheumatism or musculoskeletal disorders
and their relatives are purposefully supported and supported.
At the heart of all efforts are Lucerne and Unterwalden
is a man with his need for well-being,
Compassion and quality of life. With courses and tips
we support healthy people with prevention and information
maintaining their health. Affected by Limited
Health goes through Rheumaliga Lucerne and Unterwalden
medical, therapeutic, social and preventative measures help
come and promote self help. Services
are open to anyone interested. League for Rheumatism Lucerne i
Unterwalden is based on the guidelines of the ZEWO Foundation
(Central Office for Social Enterprises) and this one is used as
recognized as a non-profit.

About the Swiss Heart Foundation

Active against heart disease and stroke – Swiss
Herzstiftung continues its research funding and comprehensive
Educational work for fewer people
You suffer from cardiovascular disease or remain disabled,
People do not die prematurely from a heart attack or stroke and
For those affected, life is worth living. Established in 1967
The Swiss Heart Foundation is also independent of the Foundation
ZEWO mostly nonprofit certified
funded by donations.

About EIT health

EIT Health is a network of global health innovators,
supported by the EU. We work across borders
together to develop new solutions that make it European
To enable citizens to lead a longer and healthier life.
When Europeans face the challenge of increasing chronicity
Ask for disease and multi-morbidity and try out the odds
use technology that offers traditional approaches
to go beyond treatment, prevention and a healthy lifestyle,
we need thought leaders, innovators and effective ways to do this
bring innovative healthcare solutions to the market. EIT Health
meets these needs. We network all relevant network actors
Healthcare across European borders – below
Incorporating all sides of the "knowledge triangle", therefore innovation
at the interface of research, education and business to the benefit
citizens can take place. EIT Health: Together for One
healthy living in Europe. For more information: www.eithealth.eu

About the International Osteoporosis Foundation (IOF)

The International Foundation for Osteoporosis (IOF) is one
a non-profit, non-governmental foundation that acts as a global alliance
Patient societies, research institutions, medicine
Specialized staff and international promotion companies
Health functions of bones, muscles and joints. The IOF aims
empower people to take preventative measures,
To take a diagnosis and treat bone diseases, i
advocate for a change in bone health policy
become a priority in healthcare. For more
Information: www.iofbonehealth.org

About the Technical University of Munich

The Technische Universität Munich (TUM) is one of the best
Universities in Europe. It is committed to excellence in research and
Teaching, interdisciplinary education and active promotion
scientific offspring. Part of the TUM mission
is to support and promote an innovative society
facilitate an open, culturally diverse mindset
and engage in dialogue with society and the public
involved. For more information: www.tum.de

About the University of Barcelona

The University of Barcelona is one of the leading universities
Europe, often given the number of programs and
achieved excellence in research
is. The University is acting externally to provide services in the
Selecting personalized resources for lifelong learning,
Instruments to facilitate the transfer of knowledge from research,
Solutions to create market value as well as professional
Offer integration and orientation. For more information:

About BePatient

BePatient is a digital health platform it aims at
Offer eHealth solutions for patient pathways and
Improve continuity of care. The company delivers
Healthcare Database Management Specialists,
Together, developers, doctors and digital marketing experts.
BePatient has several product lines that it strives for
promote awareness of diseases and their prevention,
To support hospitalization, enlighten patients and patients
to include chronic disease management as well as one
active collaboration between patients and research
allow. For more information: www.bepatient.com.

letter of credit

   1 https://www.sheffield.ac.uk/FRAX/tool.aspx?lang=de 
   2 Wieser et. al: How much does the treatment of each major disease
cost? A decomposition of Swiss National Health Accounts, The Journal 
of Health Economnics (2018) 19: 1146-1161 
   3 Svedbom et al. Cost-effectiveness of pharmacological fracture 
prevention for osteoporosis as prescribed in clinical practice in 
France, Germany, Italy, Spain, and the United Kingdom, Osteoporosis 
International https://doi.org/10.1007/s00198-019-05064-w 
   4 https://www.rheumaliga.ch/rheuma-von-a-z/osteoporose 5 Rizzoli 
R, et al. Osteoporose in der Schweiz im Jahr 2008: eine Aufforderung 
zur Tat. Swiss Medical Forum 2008;8(42) Suppl.45 
   6 Lippuner K, et al. Remaining lifetime and absolute 10-year 
probabilities of osteoporotic fracture in Swiss men and women. 
Osteoporos Int 2009;20:1131-1140 
   7 International Osteoporosis Foundation. Stop at One. One Fracture
Leads to Another. http://ots.ch/YJMfr0. Accessed July 2019. 
   8 McCloskey E.V. et al., Osteoporosis Diagnosis and Treatment of 
Women Aged ≥70 years in Primary Care: Results From a Large 
European Cross-sectional Study.WCO IOF-ESCEOCongress, Paris France, 
April 4-7 2019, P997 
   9 The World Health Organization. Bulletin of the World Health 
Organization. Exercise interventions: defusing the world's 
osteoporosis time bomb. Available at: 
Accessed July 2019. 
   10 International Osteoporosis Foundation. Global Initiatives. 
Available at http://www.iofbonehealth.org/global-initiatives-0. 
Accessed July 2019. 
   11 Todesursachenstatistik: Sterblichkeit und deren Hauptursachen 
in der Schweiz, 2016, herausgegeben vom Bundesamt für Statistik (BFS)
2019 12 Taschenstatistik Gesundheit Schweiz 2017, herausgegeben vom 
Bundesamt für Statistik (BFS) 13 Bundesamt für Statistik, b. Maladies
cardiovasculaires. (online) Bfs.admin.ch. 2019; Available from: 
   14 Swissheart.ch. Hirnschlagkampagne - Schweizerische 
Herzstiftung. (online) Schweizerische Herzstiftung. 2019; Available 

   15 Rapsomaniki, E., et al., Prognostic models for stable coronary 
artery disease based on electronic health record cohort of 102 023 
patients. Eur Heart J, 2014. 35(13): p. 844-52. 
   16 Yusuf, S., et al., Effect of potentially modifiable risk 
factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet, 2004. 364(9438): p. 
   17 Baigent, C., et al., Efficacy and safety of more intensive 
lowering of LDL cholesterol: a meta-analysis of data from 170,000 
participants in 26 randomised trials. Lancet, 2010. 376(9753): p. 
   18 Ference, B.A., et al., Reduction of low density 
lipoproteincholesterol and cardiovascular events with proprotein 
convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an
analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists 
Collaboration. European heart journal, 2018. 39(27): p. 2540-2545. 
   19 Mach, F. et al., 2019 ESC/EAS Guidelines for the management of 
dyslipidaemias: European heart journal, 2019. 37(39): p. 2999-3058; 
European Heart Journal, ehz455, 
   20 EVOPACS Koskinas, et al. JACC 
   21 Yusuf S et al. Effect of potentially modifiable risk factors. 
INTERHEART study. Lancet 2004; 364: 937-52 in 52 countries. 
   22 Gesundheit Taschenstatistik 2017. Bundesamt für Statistik 
(BFS), www.statistik.ch 
   23 Wieser et. al: How much does the treatment of each major 
disease cost? A decomposition of Swiss National Health Accounts, The 
Journal of Health Economnics (2018) 19: 1146-1161 
   24 Kotseva K. et al., Patient and Caregiver Productivity loss and 
indirect costs associated with cardiovascular events in Europe. 
European Journal of Preventive Cardiology 0(00) 1-8. 2019. 
   25 Carrera, E., et al., Patient and caregiver productivity loss 
and indirect costs in the first year following cardiovascular and 
cerebrovascular events in Switzerland. AGLA Update Meeting, February 
7, 2019, 2019 
   26 Wieser et. al: How much does the treatment of each major 
disease cost? A decomposition of Swiss National Health Accounts, The 
Journal of Health Economics (2018) 19: 1146-1161 


Amgen Switzerland AG
Sonja Luz, phone: +41 (0) 41 369 03 71